3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Breast Neoplasms
64
Neoplasms
8
Sarcoma
6
Ovarian Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Glioma
4
Carcinoma, Non-Small-Cell Lung
4
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma
3
Liposarcoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Kidney Neoplasms
2
Interventions
Nivolumab
3
palbociclib
2
Ipilimumab
2
Imatinib Mesylate
2
relatlimab
1
pembrolizumab
1
camrelizumab
1
apatinib
1
Specimen Handling
1
Radiotherapy
1
Radiation
1
Protons
1
Proton Therapy
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Disulfides
1
Dasatinib
1
Cetuximab
1
CTLA-4 Antigen
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Chordoma
×
palbociclib
×
Clear all
NCT03242382
2024-01-23
PalboSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
40 enrolled
NCT03110744
2023-03-27
NCT-PMO-1601
University Hospital Heidelberg
Phase 2
Completed
43 enrolled